Predicting Drugs' Commercial Potential: No Crystal Ball Yet, but Can We Get Closer to One?

Posted by Yasasvi Popuri on Wed, Feb 05, 2020

Emily Mandell co-wrote this blog post with Yasasvi Popuri.

What clinical profile should our pipeline drug pursue to compete in a crowded market? For which patients will our drug be preferred and why? How will the adoption of our in-market drug change with upcoming biosimilars, competitive launches and changing guidelines? These multibillion-dollar questions are very familiar to commercial and medical teams of pharmaceutical and biotech companies, but just how do they feel about answering them? Simply put: uncertain.


>
Read More

From Good to Great: To Accelerate Growth, Look Inward

Posted by Yasasvi Popuri on Thu, Nov 08, 2018

How can we identify and realize growth opportunities? That’s the multibillion-dollar question that looms large on the minds of pharma and biotech companies when their drugs enter the maturation phase. In our experience, pharmaceutical and biotech companies take one of two broad approaches to address this problem: understanding and addressing the provider, patient or payer barriers or diving deeper into field force effectiveness to improve the customer experience. The choice of approach depends on whether marketing or sales leadership initiates the franchise-wide pursuit of additional growth opportunities.


>
Read More